Shares of HCW Biologics slid 16% to $1.12 on May 19, after a blistering rally that had tripled the stock from $0.34 to $1.34 in a single session last week. The catalyst for that surge — a one-time licensing deal that made Q1 look profitable — is now being reassessed by traders who see a company still teetering on the edge of survival.
A Single Deal Made the Entire Quarter — and It Won't Repeat. Q1 2026 revenue rose to $6.54 million from just $5,065 a year earlier, primarily from a $6.5 million licensing agreement with Beijing Trimmune.
The deal generated a $3.5 million cash fee and a $3.5 million equity interest. Strip away that single transaction and the company had virtually zero revenue. Net income swung to $3.47 million from a $2.2 million loss. That profit headline fueled the rally, but investors are now recognizing it was a one-off, not a sign of recurring business.
The Cash Vault Is Nearly Empty. As of March 31, cash stood at just $1.23 million, while management disclosed cumulative net losses of $102.3 million and explicitly stated "substantial doubt" about continuing as a going concern — accounting language meaning the company may not survive the next 12 months without fresh money. Current liabilities totaled $19.96 million , dwarfing available cash roughly 16 to 1.
Nasdaq Delisting Risk Hangs Over Every Trade. On March 26, the company received notice it had again fallen out of compliance with Nasdaq's $1.00 minimum bid price rule.
On May 5, HCW Biologics was granted a hearing to appeal a Nasdaq staff determination to delist its securities. A failed appeal would push shares to over-the-counter markets, likely crushing liquidity and scaring off institutional holders.
Cost Cuts Are Real but Tiny Relative to the Hole. R&D and general expenses declined 15% and 18% year-over-year , but these savings amount to only a few hundred thousand dollars — immaterial against $21.6 million in total liabilities. A $20 million standby equity purchase agreement exists but depends on market conditions and shareholder approval , neither of which is guaranteed at this price.
Today's selloff reflects a market waking up from a sugar high. Without recurring revenue, new capital, or a favorable Nasdaq ruling, HCWB's brief moment of profitability may be remembered as the exception that proved the rule.